Avidity Biosciences (NASDAQ:RNA) Earns Strong-Buy Rating from Analysts at Raymond James
Analysts at Raymond James assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a report released on Wednesday, Marketbeat.com reports. The brokerage set a “strong-buy” rating and a $65.00 price target on the biotechnology company’s stock. Raymond James’ target price suggests a potential upside of 102.24% from the stock’s previous close. […]
Analysts at Raymond James assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a report released on Wednesday, Marketbeat.com reports. The brokerage set a “strong-buy” rating and a $65.00 price target on the biotechnology company’s stock. Raymond James’ target price suggests a potential upside of 102.24% from the stock’s previous close. […]
